54 results about "Fecal microbiota" patented technology

The discovery and application of immune checkpoint inhibitors (ICI) have significantly promoted cancer treatment. However, the response rate is still low in gastrointestinal (GI) cancers. To explore novel adjuvant treatment options, we performed fecal microbiota transplantation (FMT) of healthy donors on 10 GI cancer patients with resistance to anti-PD-(L) 1 treatment. The combination of FMT and anti-PD1 treatment was well tolerated and no serious adverse reaction was observed. Two out of 10 patients restored clinical responsiveness to anti-PD1 after FMT. Clinical benefits were shown to be associated with better colonization of co-occurred immunogenic microbes from donors, alongside activated immune status reflected by the peripheral immune cell population. Moreover, we identified microbial signatures of ICI responsiveness and validated in an independent cohort. Our study demonstrates the feasibility of FMT as a potential adjuvant therapy for ICI irresponsive GI cancer patients and laid a foundation for LBP / consortia development to enhance ICI efficacy.

The invention relates to a flora transplantation clinical pathway standardization management method, device and equipment and a medium. The method comprises the following steps: on the basis of clinical data of a patient and screening data of a donor, executing flora suitability evaluation by using a deep learning model and selecting an adaptive donor; obtaining a flora sample of an adaptive donor, and carrying out high-throughput sequencing; generating a donor flora quality evaluation score according to a preset flora composition diversity index based on a sequencing result; screening the flora samples of which the quality evaluation scores are higher than a preset quality threshold value to prepare a flora preparation; detecting activity parameters and diversity parameters of the flora preparation, and performing colonization potential classification prediction by combining clinical data of the patient and adopting a support vector machine algorithm so as to output a potential colonization success rate; and when the potential colonization success rate exceeds a preset success rate threshold, outputting a clinical transplantation scheme through a preset transplantation scheme generation algorithm based on the flora preparation and the clinical data of the patient. According to the method, through multi-stage intelligent decision making, the safety and the effectiveness are improved.

Disclosed herein are methods for administering a dose of a microbiota recovery therapy composition by colonoscopy. The methods disclosed herein are useful for the treatment of diseases and / or conditions of the digestive tract, such as Clostridium difficile infection (GDI), including recurrent GDI, and other gastrointestinal disorders. The method can result in improved quality of life. These methods are capable of altering the gut microbiota composition and / or the gut metabolome composition. The microbiota recovery therapy composition comprises a fecal microbiota suspension comprising: a fecal microorganism derived from a human fecal sample, and a solution of polyethylene glycol and brine.

The present invention discloses an antibody against Clostridium difficile specific protein, a magnetic bead-antibody conjugate and its application. The monoclonal antibody is any one of monoclonal antibody CD1, monoclonal antibody CD2, monoclonal antibody CD3 and monoclonal antibody CD4. The magnetic bead-antibody conjugate is formed by conjugating a monoclonal antibody with activated carboxyl magnetic beads to obtain the magnetic bead-antibody conjugate. Based on the magnetic bead-antibody conjugate sorting method, antibody magnetic beads that couple and recognize the Clostridium difficile secreted proteins TcdA, TcdB, the highly expressed GDH on the surface of Clostridium difficile, and the LPxTG of Clostridium difficile are used to capture Clostridium difficile, achieving the purpose of rapidly isolating Clostridium difficile from fecal samples. The present invention is based on the immunomagnetic bead separation technology of antigen-antibody reaction for separation, with the characteristics of being rapid, simple, having high enrichment efficiency and strong specificity. The present invention can be used to isolate and remove Clostridium difficile in fecal microbiota transplantation, and can also be used for strain identification and sequencing.

The invention belongs to the field of microbiology and bioinformatics, and particularly relates to a USCG-based intestinal flora probiotic recognition method, which is characterized in that a ucgMLST technology is utilized, metagenome data is analyzed to realize strain-level resolution, and 39 candidate probiotics are screened out in combination with species retention rate and clinical outcome data; the method can realize accurate detection of low-abundance species, and is especially suitable for research and scenes such as fecal fungi transplantation (FMT) donor screening, receptor treatment effect prediction, probiotic development and the like.

Provided are a method for predicting a treatment response to cancer immunotherapy, the method comprising a step of evaluating, from feces isolated from a patient, the enrichment of a strain of the order TANB77 according to GTDB phylogenetic classification or taxa belonging to the order TANB77, and a step of predicting a treatment response of the patient to cancer immunotherapy on the basis of the enrichment of the order TANB77 or the taxa; a probiotics composition for improving a treatment response; a fecal microbiota transplantation composition; and a method for screening for candidate prebiotics by using same.

The application discloses a kind of based on 5 kinds of bacteria combination's flora transplantation donor screening technique and its application in tumor immunotherapy, the intestinal flora includes Eubacterium rectale, Adlercreutzia equolifaciens, Megamonas hypermegale, Lachnospiraceae bacterium (5_1_63FAA), Gordonibacter pamelaeae One or more of them.The application is screened and found that the abundance of the intestinal flora in the obese cancer patients with immune checkpoint inhibitor treatment response is significantly improved, and can be used to predict the immune checkpoint inhibitor treatment effect of cancer patients.The flora transplantation preparation containing the relative abundance of the intestinal flora is greater than or equal to 8.51%, and after combination treatment with immune checkpoint inhibitor, the tumor immunotherapy effect can be significantly improved.

Methods and compositions relating to sterilized fecal microbiota and compositions derived from the same. A method of sterilizing a fecal composition to obtain a sterilized fecal composition is provided. Methods of further purifying the sterilized composition and optionally freezing or freeze-drying the compositions is also provided. Methods of using the compositions for treatment in beverages, foods, and in supplements are also provided.

The invention discloses a microbial marker for treating recurrent clostridium difficile infection based on coprophilous fungus transplantation and a screening method of the microbial marker. The microbial marker comprises the following components: Dorea longigena, Alistipes putredinis, Citrobacter farmeri, Coprococcos, Eubacter coprostanoliganes, Agatrobacter rectas, Dorea foetida, Blauria obbe, Klebsiella foetida, Blauria foetida, Blauria ovaticus and Gemmigerformation. The microbial marker comprises the following components: Dorea longigena, Alistipes putredinis, Citrobacter farmeri, Citrobacter coprostanoliganes, Citrobacter rectas, according to the invention, through metagenome sequencing and a machine learning algorithm, key microbial markers significantly related to recurrent clostridium difficile symptom improvement in the coprophilous fungus transplantation treatment process are screened out, and a scientific basis and a standardized scheme are provided for coprophilous fungus transplantation treatment of recurrent clostridium difficile infection.

The invention discloses extraction and application of uric acid reducing active components of gynura procumbens, and relates to the technical field of traditional Chinese medicine efficacy material basis and action mechanism research, and the method comprises the following steps: extract preparation, intestinal flora regulation effect verification, flora intermediary effect verification through coprophilous fungus transplantation, and action mechanism verification. In the invention, in the aspect of mechanism, a flora-host co-metabolism theory is introduced, and a new idea that the extract can indirectly influence uric acid metabolism through intestinal local regulation flora is provided; in the aspect of flora regulation, the extract can specifically improve the abundance of A. indinctus by about 2 times, the hippuric acid generation amount is accurately promoted to be increased by 30.3%, and the uncertainty of conventional intervention is avoided; a coprophilous fungus transplantation experiment shows that the uric acid reducing effect of flora transplantation is obviously superior to that of a pure component effect, and a brand new uric acid reducing mechanism is disclosed; in an application scene, the traditional uric acid reducing way is bypassed, the intestinal ABCG2 pathway is activated, and a new hope is brought to a drug-resistant patient.

The utility model belongs to the technical field of coprophilous fungi transplantation, and particularly relates to a coprophilous fungi transplantation bacteria-liquid separation device which comprises a box body and a collection frame, a box cover is arranged at the top of the box body, a liquid inlet pipe is arranged on the box cover, supports are arranged on the inner wall of the box body, a filter screen is connected between the two supports, and a liquid outlet pipe is arranged on the liquid inlet pipe. The filtering net is fixedly connected with the front wall and the rear wall of an inner cavity of the box body, inserting grooves are symmetrically formed in the side wall of the support and the inner wall of the box body, and inserting blocks corresponding to the inserting grooves are arranged on the side wall of the collecting frame. Residues such as particulate matters are prevented from being accumulated on the filter screen to cause blockage, the filtering effect is ensured, the residues such as particulate matters are conveniently discharged, and cleaning operation is convenient.

The invention relates to an intestinal flora freeze-drying protective agent which comprises 0.5%-2% of trehalose, 12%-25% of edible substances and the balance of water, and the edible substances comprise prebiotics, a homogenizing agent, fermentable dietary fibers and an antioxidant. The invention further relates to application of the intestinal flora freeze-drying protective agent in coprophilous fungus transplantation, intestinal flora freeze-dried powder and a preparation method of the intestinal flora freeze-drying protective agent. According to the intestinal flora freeze-drying protective agent, the survival rate of the intestinal flora in the freezing or freeze-drying process can be remarkably increased, the colonization effect of the intestinal flora in a receptor is optimized, and therefore the overall effect of FMT treatment is improved.

The invention discloses a method for constructing a coolah source elderly mouse model by using a coprophilous fungus transplantation technology, and belongs to the technical field of biomedicine. According to the method, C57BL / 6N mice are selected and normally fed in groups; the method comprises the following steps: freely drinking antibiotics to construct a sterile environment, and constructing a coolah source old-age mouse model by utilizing a coprophilous fungus transplantation technology; during the test, apparent states such as diet, activity, mental state and defecation of the mouse are observed, and after the test is finished, the expression quantity of senescence factors of each tissue of the mouse is detected by a qPCR (quantitative polymerase chain reaction) method. Test results show that the expression quantity of aging factors of mice can be increased successfully after 6-week intragastric administration of the colacobacterium colati suspension, and it is proved that the mice have aging characterization. The model has obvious advantages and wide application prospects in the aspects of clarification of the aging pathogenesis of the organism and drug research and development, can deeply study drug use of colaz, ensures that colaz is properly treated and potential side effects are minimized, and better improves the safety of drug use.

This invention relates to fecal microbiota transplantation (FMT) formulations for treating lung cancer, their screening methods, and applications. The invention establishes a microbiome-based quantitative screening system based on the characteristics of the lung cancer immune microenvironment, achieving a precise match between donor screening criteria and tumor-specific immune regulation needs. This overcomes the limitations of traditional FMT formulation preparations that rely on universal health standards, providing reliable support for clinical applications. Furthermore, the invention develops a combined application strategy of FMT formulations and immune checkpoint inhibitors, which can significantly improve disease control rates and prolong progression-free survival in lung cancer patients, providing an innovative solution to overcome drug resistance challenges in lung cancer immunotherapy.

Provided herein are methods of analyzing a fecal sample including measuring the amount of ethanol produced by the fecal sample and measuring the presence, absence, or relative abundance of Ruminococcus gnavus, Escherichia coli, or Klebsiella pneumoniae in the fecal sample compared to a reference sample, and / or measuring the expression of genes associated with the heterolactic fermentation pathway, the mixed acid fermentation pathway, the ethanolamine utilization pathway, and / or acetylene degradation pathway. Also provided herein are methods of treating a condition associated with gut alcohol production in a subject including analyzing a fecal sample from a subject, determining the subject has a gut alcohol production condition, and administering to the subject an effective amount of a treatment comprising a probiotic with optional resistant starch, fecal microbiota transplantation (FMT), an antimicrobial agent, a microbial enzyme inhibitor, or a combination thereof.

The present disclosure provides freeze-dried compositions that include an extract of human feces and a flavoring agent, where the compositions, upon reconstitution with a liquid, have no objectionable odor and has no objectionable taste. Also provided are methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease. In some embodiments, the subject can be an individual with reduced ability to swallow, such as pill dysphagia, or an individual refractory to administration of a liquid having an objectionable odor or objectionable taste.

This invention discloses a dietary factor and its combination that targets gut microbiota to improve exercise performance, belonging to the fields of microbial technology and pharmaceutical technology. Experimental verification shows that the dietary factor combination can increase the abundance of *Eubacterium rectale*, *Faecalibacterium prausnitzii*, and *Veillonella* species; a combination of galactooligosaccharides, burdock seed, matsutake polysaccharide, and galactooligosaccharides; a combination of burdock seed and matsutake polysaccharide; and a combination of burdock seed and galactooligosaccharides can increase the concentration of fatty acid amides; curcumin and the combination of curcumin, burdock seed, and galactooligosaccharides show the best effect in promoting the content of fecal microbiota after acetic acid fermentation; and a mixed combination of *Bifidobacterium adolescentis* CCFM1066, *Bifidobacterium longum* CCFM1306, curcumin, inulin, burdock seed, matsutake polysaccharide, and galactooligosaccharides shows the most significant effect in increasing the time spent swimming at exhaustion under load in exercised mice.

This invention discloses a method for characterizing and isolating gut microbiota capable of specifically uptake or metabolizing natural products, comprising: in vitro co-culture, click chemistry reaction, and flow cytometry sorting. Based on click chemistry technology, this invention co-cultures alkyne-modified natural products with fecal microbiota. Through a copper-catalyzed azido-alkynyl cycloaddition reaction, azidolated fluorescent dyes are labeled onto all bacteria capable of uptake and utilizing natural products or their metabolites. These bacteria are then isolated using flow cytometry sorting. Compared to methods for studying metabolism and utilization using single-species culture, this invention is lower in cost and shorter in time, providing a new approach for extensive and in-depth research on the interaction between gut microbiota and natural products.

The invention belongs to the technical field of coprophilous fungus transplantation, and particularly relates to a coprophilous fungus transplantation combined preparation and a method for combined treatment of intestinal diseases by combining coprophilous fungus transplantation with miR-146b. The coprophilous fungi transplantation combined preparation disclosed by the invention comprises coprophilous fungi and miR-146b. The invention creatively provides a coprophilous fungus transplantation and miR-146b combined therapy, and the coprophilous fungus transplantation and miR-146b combined therapy can achieve the following beneficial effects: the flora colonization rate is increased: the host intestinal microenvironment is adjusted through miR-146b, and the colonization capability of transplanted flora is enhanced; the miR-146b can inhibit the transcriptional activity of pathogenic bacteria (such as enterobacteriaceae) in a targeted manner, and can promote the functional expression of anti-inflammatory bacteria at the same time; and the safety risk is reduced: the proliferation of potential pathogenic bacteria in transplanted flora can be inhibited by miR-146b, and the adverse reaction is reduced.

In alternative embodiments, provided are products of manufacture and methods for treating, ameliorating and preventing diseases and conditions related to infected or dysfunctional mucosal surfaces, including mucosal surfaces in the gastrointestinal (GI) tract, respiratory tract, and other mucosal surfaces, for example, mucosal surfaces in the stomach, nasal sinuses, nasopharyngeal area, lungs, bladder or the vagina. Provided are methods and products of manufacture for preparing the GI tract for a microbiota engraftment, then infusing a colonic microbiota engraftment, for example, a fecal microbiota transplant (FMT). In alternative embodiments, provided are methods and products of manufacture for mechanical disruption of a biofilm followed by the chemical and / or biologic dissolution of a mucus layer or a biofilm, and subsequent implantation of FMT material into or onto a mucosal surface such as a GI tract. In alternative embodiments, provided are delivery devices which permit the FMT material to reach the various mucosal surfaces, for example, mucosal surfaces in the GI tract. In alternative embodiments, provided are methods and products of manufacture for replacing an individual's microbiome, where the individual's microbiome may be infected, including replacing the individual's microbiome in colonic, intestinal, gastric, respiratory or vaginal spaces or environments, with that of a healthy or not infected microbiome, where the healthy or not infected microbiome can be donor-derived or cultured. Provided herein are methods for the treatment, amelioration and / or prevention of numerous conditions characterized by an in situ microbiome super-infection, including microbiome super-infections, for example, conditions characterized as gastrointestinal (GI) disease.

The present application relates to a quality control product for quality evaluation of a preparation for intestinal flora transplantation, a preparation method and application thereof. The quality control product comprises a complex microbial component, an internal standard component, a simulated matrix and a stabilizer. The present application adopts a "multi-donor mixing" method, and compared with a scheme based on cultured strains, the quality control product prepared by the present application is highly consistent with a real FMT preparation in terms of species composition, relative proportion and bacterial activity state, and the quality control result has a strong clinical relevance. By constructing a "core bacterial spectrum", the complex flora quality control becomes simple, focused and cost controllable. In addition, the use of bifidobacterium as an internal standard has better compatibility with the sample matrix, more accurate monitoring and completely eliminates the risk of exogenous contamination.

The invention relates to the technical field of oral microbial preparations, and particularly discloses a coprophilous fungus transplantation microcapsule preparation method and application thereof, and the preparation method comprises the following steps: coprophilous fungus suspension acquisition, layer-by-layer embedding, calcium / zinc reinforcement, coprophilous fungus microcapsule freeze-drying and the like. The carboxymethyl chitosan, the sodium alginate / sulfated polysaccharide, the calcium ions and the like are used as raw materials, the hydrogel with a double-network structure is prepared through specific ionic crosslinking and electrostatic adsorption reaction, and the hydrogel has excellent mechanical performance and stability and can effectively protect coprophilous fungi from being damaged by the external environment. The prepared double-network hydrogel is used as a wall material, coprophilous fungi are wrapped in the double-network hydrogel to form coprophilous fungi microcapsules, and the variety of receptor intestinal flora communities after coprophilous fungi transplantation is effectively enhanced.

The invention discloses application of lactobacillus mucous membrane to preparation of a product for treating hyperlipemia periodontitis, and belongs to the technical field of biological medicine. Through multi-omics analysis, a mouse model and fecal flora transplantation, the significant exhaustion of the intestinal mucosal lactobacillus mucilaginosus is clearly identified as a key feature of a hyperlipemia periodontitis patient and a mouse, and further experiments prove that the pathological progress of the hyperlipemia periodontitis can be significantly alleviated by oral administration of the live mucosal lactobacillus mucilaginosus; comprising reducing alveolar bone loss, improving bone microstructure and inflammatory conditions, while systematically restoring host microbial and metabolic homeostasis. According to the invention, the lactobacillus mucous membrane is determined as a key microbial intervention means for treating the hyperlipemia periodontitis for the first time, and a technical thought is provided for treating the hyperlipemia periodontitis.

Certain microorganism species in the gut and feces of fecal microbiota transplantation (FMT) donors can affect the outcome of FMT treatment. Thus, novel methods are provided for identifying subjects as suitable donor to optimize FMT outcome and for pre-treating donors and / or receipients for optimized FMT outcome. Also provided are kits and compositions for improving FMT outcome, including for specific purposes such as for weight loss or cholesterol reduction.

A method of treating an individual with a health condition comprising the steps of: a) screening the individual to determine a level of severity of the health condition; b) acquiring a fecal sample from the individual; c) processing the fecal sample; d) sequencing the fecal sample to determine the individuals microbiome; e) analyzing the sequenced fecal sample, wherein the step of analyzing the sequenced fecal sample comprises: i) comparing the individual's microbiome to the microbiome of a parent of individual; ii) comparing the individual's microbiome to the microbiome of a sibling of the individual; iii) comparing the individual's microbiome to the microbiome of another individual with same health condition; and iv) comparing the individual's microbiome with a health condition to the microbiome of the individual before they acquired the health condition; f) administering vancomycin to the individual; g) performing the fecal microbiota transplant; and h) monitoring the individual.

Disclosures herein relate to methods of producing oral powdered compositions for fecal microbiota transplant including desired microbes and related methods of treatment. Procedures for producing the powdered composition may include filtering a fecal sample, separating particulate matter of the filtrate, repeatedly resuspending the sediment and separating particulate matter, diluting the supernatant and repeatedly separating particulate matter out of the supernatant, resuspending the sediment in a cryoprotectant to obtain a mixture, and freeze-drying the mixture to obtain a freeze-dried, powdered composition, wherein the powdered composition may be substantially tasteless, odorless, and colorless. The FMT composition has an odor as evaluated with a confidence of 95% to be odorless for more than 50% of the population using a triangular test and a flavor as evaluated with a confidence of 80% to be flavorless for more than 50% of the population using the triangular test.

The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of living microorganisms and one or more pharmaceutically acceptable water absorbing excipient(s), wherein the composition has a water content, determined according to European Pharmacopoeia 9.4, section 2.5.12., from 0.5 to 30% with respect the total weight of the composition.The invention also provides processes for its preparation as well as it use in therapy.The live-cell based composition of the invention is stable at mild conditions.

The present disclosure provides freeze-dried compositions that include an extract of human feces and a flavoring agent, where the compositions, upon reconstitution with a liquid, have no objectionable odor and has no objectionable taste. Also provided are methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease. In some embodiments, the subject can be an individual with reduced ability to swallow, such as pill dysphagia, or an individual refractory to administration of a liquid having an objectionable odor or objectionable taste.

The coprophilous fungus transplantation catheter comprises a stomach tube, a first coil is fixedly arranged at the front end of the stomach tube, a second coil is fixedly arranged at the position, 4-6 cm away from the front end, of the stomach tube, and a first pull wire is fixedly arranged at the front end of the stomach tube; the first coil and the second coil are used for being matched with the titanium clip to fix the intestinal wall when the catheter is placed in; the free end of the first traction line penetrates in from the front end of the endoscope and penetrates out from a biopsy hole channel of the endoscope when the catheter is placed in; the invention provides a coprophilous fungus transplantation catheter based on stomach tube structure improvement and a synchronous implantation method, and solves the key technical operation bottlenecks of colonoscopy implantation: long operation time, low implantation success rate, poor patient tolerance and high cost; the operation duration is shortened by 50%, the success rate is improved, the uncomfortable degree of a patient is improved, the cost is reduced by more than 90%, and complications are reduced.

The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of live microorganisms and one or more pharmaceutically acceptable water-absorbing excipients, wherein the water content of the composition is between 0.5% and 30% by weight of the total composition, as determined according to the European Pharmacopoeia 9.4 section 2.5.12. The present invention also provides a process for its preparation and its use in therapy. The live cell-based composition of the present invention is stable under mild conditions.